

**SNIPR BIOME elects Dr. Per Falk, MD, PhD, President, Ferring Pharmaceutical to become member of its Board of Directors**

Copenhagen, September, 2020

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the election of Dr. Per Falk, MD, PhD, President of Ferring Pharmaceuticals, to become member of its Board of Directors.

Per joined Ferring Pharmaceuticals in 2015 and was appointed President from Jan 2019. Prior to joining Ferring, Per held executive and senior leadership positions at Novo Nordisk and AstraZeneca in research, medical and clinical development roles. For over 30 years, Per has been investigating and evolving microbiome science, holding faculty positions at some of the world's leading institutions to advance research in this field. During his career, he has held the role of Associate Professor at the Karolinska Institute, Sweden and the Washington University School of Medicine, USA. Per is a qualified medical doctor and holds a Ph.D.

Dr. Christian Elling, Chairman of the SNIPR BIOME Board of Directors, Managing Partner, Lundbeckfonden Emerge commented: "As a highly respected and seasoned R&D executive, Dr Per Falk brings decades of experience of building value in innovative commercial research and development organisations, that will be valuable in our efforts of bringing new breakthrough medicines to patients and physicians. On behalf of SNIPR BIOME and the board, I welcome Per and look forward to drawing upon his strategic and operational judgment."

Dr. Per Falk, President of Ferring Pharmaceuticals commented: "I am honoured to join the SNIPR BIOME Board of Directors and be part of an exciting journey bringing cutting edge microbiome innovation to patients. SNIPR BIOME has developed a unique and strong technology platform that holds the promise of changing the way we manage many serious diseases, including the rapidly expanding threat from multi-resistant bacteria."

Dr. Christian Grøndahl, Co-founder & CEO commented: We warmly welcome Per to join our board of directors. Per's extensive experience in medical and clinical drug development and his in-depth knowledge of the microbiome and it's vast potential both as a leading scientist, physician and business executive makes him a very strong addition to our board. I look forward to working closely with Per in designing tomorrows CRISPR-based medicines to threat life threatening infections and improve treatments of inflammatory and malignant disorders.

For more information, please contact:

Co-founder & CEO, Christian Grøndahl / E-mail: [cg@sniprbiome.com](mailto:cg@sniprbiome.com) / Mobile: +45 20202747

*About SNIPR BIOME*

SNIPR BIOME is a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patent-protected CRISPR/Cas platform. The company applies its CRISPR technologies to address medical needs, such as infectious diseases, inflammatory conditions and immuno-oncology. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient's microbial community intact. In March 2019, SNIPR BIOME closed a \$50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).

For more details, please visit: [www.sniprbiome.com](http://www.sniprbiome.com)